Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bionano Genomics Inc (NQ: BNGO )

0.2240 +0.0049 (+2.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bionano Genomics Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: 
Via Benzinga
Wait for Bionano Stock to Fall Further Before Buying
BNGO stock is breaking down following the latest earnings report, and there are no major catalysts to push shares up in the short term. 
Via InvestorPlace
Bionano’s Is on Track for Growth Thanks to Saphyr
BNGO stock beats analyst forecasts yet again. Flush with cash and with Saphyr installations rising, this stock remains a high potential play. 
Via InvestorPlace
With Progress on Multiple Fronts, Bionano Genomics Stock Is Great Buy Here
Bionano's acquisition of a software company makes Saphyr more attractive, and studies should result in insurers reimbursing those who use the system. BNGO stock is a buy. 
Via InvestorPlace
Bionano Genomics, Inc (BNGO) Q3 2021 Earnings Call Transcript
BNGO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Unusual Options Activity Insight: Bionano Genomics
Bionano Genomics (NASDAQ:BNGO) shares experienced unusual ... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 16.73% to $14.86 during Tuesday's regular session. The current volume of 1.0 million shares is 269.7%... 
Via Benzinga
2 Best Biotech Stocks to Buy in November
Bionano Genomics and Ocugen could both be gearing up for a healthy rally this month. 
Via The Motley Fool
Bionano Genomics Is Still Set to Pay Off Big for Patient Investors
BNGO stock is no longer a fast money trade. But that's hardly a reason to skip out on it, given its massive potential. 
Via InvestorPlace
Jim Cramer Prefers This Stock Over Mogo, Considers Endeavor Group As Inexpensive
On CNBC’s "Mad Money Lightning Ro... 
Via Benzinga
Bionano Genomics’ Latest Software Business Acquisition Adds Immense Value
BNGO stock isn't a darling of the markets at the moment, but Bionano continues to advance its stature in the optical genome mapping niche. 
Via InvestorPlace
Bionano Genomics Stock Looks Ready to Reward Patient Investors
BNGO stock is down 25% since year to date. But as the company begins to deliver consistent revenue, a prudent investment may be rewarded. 
Via InvestorPlace
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
What's Up With Bionano Genomics Today?
Bionano Genomics Inc. (NASDAQ: BNGO) shares are trading higher Tuesday after the company announced it agreed to buy BioDiscovery Inc, a provider of software for analysis,... 
Via Benzinga
BNGO Stock: The Big Acquisition News Sending Bionano Genomics Soaring
Bionano has just made a deal that will help it secure a spot among biotech companies riding the wave of the current boom. BNGO stock is up. 
Via InvestorPlace
Exposures COVID-19
Groundbreaking Tech Makes Bionano Genomics Look Better Than Ever
Off and on the price chart, Bionano Genomics could be the next big thing in genomics with multiple catalysts for BNGO stock. 
Via InvestorPlace
BNGO Stock: What Is Driving Bionano Genomics Higher Today?
Today, investors in Bionano Genomics and BNGO stock are cheering some positive clinical trial data around optical genome mapping. 
Via InvestorPlace
Bionano Genomics Remains Promising With Global Product Adoption
BNGO stock has been stuck in a range, but its next move should be to the upside based on Bionano's breakthrough genome mapping system. 
Via InvestorPlace
If You Invested $1,000 In BioNano Stock One Year Ago, Here's How Much You'd Have Now
Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return over the last 12 months is 37.1... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Price Is Right for BioNano Genomics Given Saphyr’s Potential
With its Saphyr system seeing adoption ramp up, the long-term growth potential for BNGO stock is considerable. 
Via InvestorPlace
Bionano Stock Will Soar as the Company’s Diagnostic System Catches On
As more payors reimburse labs for using Bionano's Saphyr device, the company's financial results will improve, lifting BNGO stock. 
Via InvestorPlace
Faster and Better Clinical Outcomes Make the Case for Bionano Genomics
Bionano Genomics is mastering the science of genome mapping, while a reduced-price BNGO stock has a clear path forward for investors. 
Via InvestorPlace
Bionano Genomics, Inc (BNGO) Q2 2021 Earnings Call Transcript
BNGO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Bionano’s Technology Is Interesting, But Its Earnings Are Uninspiring
Bionano could become a decent testing company within its niche. However, BNGO stock has run far ahead of the company's fundamentals. 
Via InvestorPlace
AMC Entertainment Tops Q2 Trends For Millenials And Gen Z, WISH Enters The Top 100
A quarterly report from Apex Clearing shows what the top owned stocks are among Millenials and Gen Z. Here is a look at the top holdings and the biggest movers from the first... 
Via Benzinga
Weak Fundamentals Prove There Is No Reason to Buy Bionano Genomics
Bionano Genomics is risky and its valuation does not justify its price. There is no compelling argument for a buy in BNGO stock. 
Via InvestorPlace
You’d Be Wrong to Paint Bionano Genomics Stock With the Meme-Stock Brush
With Bionano's disruptive tool, Saphyr, poised to revolutionize the DNA analysis sector, investors should definitely look to buy BNGO stock on its recent dip. 
Via InvestorPlace
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.